Y.S.P. Southeast Asia Holding Bhd.
MMYX:YSPSAH1.96
MYR
+0.03
(+1.55%)
ISIN
MYL7178OO006
Return %
Stock
S&P 500
1Y
-8.84
14.20
3Y
-20.97
81.12
5Y
-1.51
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Fang Hsin Lee
- Full Time Employees
- 1,430
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Kuala Lumpur Malaysia
- IPO Date
- Dec 23, 2003
- Website
- yspsah.com
- Similar Companies
- Business
- Y.S.P. Southeast Asia Holding Bhd. is a Malaysia-based investment holding company that operates primarily as a manufacturer, trader, and distributor of generic pharmaceuticals, over-the-counter (OTC) medicines, veterinary formulations, traditional herbal products, and consumer healthcare products. Founded in 1987 and headquartered in Kuala Lumpur, Malaysia, the company conducts its primary manufacturing and laboratory operations through its key operating subsidiary, Y.S.P. Industries (M) Sdn. Bhd., situated in Bandar Baru Bangi, Selangor. The group operates across three core business segments: Manufacturing, Trading, and Investment Holding, serving public healthcare institutions, private hospitals, medical clinics, commercial pharmacies, livestock farms, and retail consumers across Southeast Asia and international export markets. The company provides a broad and systematic portfolio of healthcare products and contract services, comprising generic prescription and OTC pharmaceuticals across multiple therapeutic areas, including cardiovascular, alimentary tract and metabolism, systemic anti-infectives, musculoskeletal, central nervous system, respiratory, and dermatological agents; oral solid dosage forms, including standard tablets, film-coated tablets, hard gelatin capsules, and enteric microencapsulated capsules; liquid formulations, including oral syrups, suspensions, and solutions; semi-solid topical preparations, including therapeutic creams, ointments, and gels; sterile preparations, including ophthalmic eye drops, ear drops, and liquid injections; rectal suppositories; veterinary health and aquaculture solutions, including animal therapeutic drugs, feed additives, nutritional premixes, and biosecurity sanitizers; complementary and Traditional Chinese Medicine (TCM) formulations, including concentrated herbal extracts, capsules, and granule preparations manufactured and distributed in partnership with Sun Ten Pharmaceutical Co. Ltd.; health food and dietary supplements, including vitamins, minerals, botanical wellness blends, and lifestyle health products marketed under proprietary labels such as GREENS; medical devices and cosmeceutical supplies; and comprehensive Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services spanning product formulation, analytical method validation, stability testing, regulatory dossier registration, and commercial packaging. Geographically, Y.S.P. Southeast Asia Holding Bhd. maintains operational subsidiaries, representative offices, and distribution networks throughout Malaysia, Singapore, Vietnam, the Philippines, Myanmar, Cambodia, Thailand, Indonesia, Brunei, and Laos, while exporting products to regional markets across East Asia, South Asia, the Middle East, Africa, Oceania, and North America. The company maintains an established affiliation with Taiwan-based Yung Shin Pharmaceutical Industrial Co., Ltd., facilitating ongoing access to shared technical research, manufacturing technology transfers, and cross-border commercial opportunities. In recent developments, Y.S.P. Southeast Asia Holding Bhd. has focused on expanding its regional market penetration and advancing its generic pharmaceutical pipeline through targeted regulatory filings across ASEAN markets. The group has undertaken strategic upgrades to its Good Manufacturing Practice (GMP) compliant manufacturing infrastructure and automated warehouse logistics in Selangor to increase batch throughput, improve supply chain efficiency, and satisfy rising regional demand for affordable generic medicines. In consumer healthcare, the company has broadened its wellness portfolio through the product expansion and market activation of its GREENS botanical nutrition brand, deploying targeted lifestyle campaigns to capture rising demand in the preventative health sector. Concurrently, the group continues to expand its CDMO partnerships and deepen collaborative distribution initiatives with Sun Ten Pharmaceutical, reinforcing its presence in certified herbal medicines and integrated healthcare supply channels across domestic and international markets.